中国造埃博拉药物挽救生命却卷入专利纠纷_时事

中国造埃博拉药物挽救生命却卷入专利纠纷

ZMapp的生产在去年秋冬陷入困难，很快就断供了，一家叫作“北京天广实生物技术有限公司的小型中国民营公司因此迎头赶上，制造了100剂MIL77。这意味着有更多绝望的病人可以得到挽救生命的治疗。但侵犯专利权的问题已经引起美国官员注意，而实验性的埃博拉疗法何时应该仅限于在严格管控的研究中施用，何时应该基于同情心提供给更多人，各方的看法也存在分歧。

Feng Li, chief executive of Beijing Mabworks, said his company was motivated to fight aglobal emergency and had made a licensing agreement with ZMapp’s intellectual propertyrights holder. “People think international collaboration could easily happen between the U.S.and Canada, he said, “but these days, China could play a role by making emergency responsedrugs “better and faster in some cases.

天广实的首席执行官李锋表示，公司是希望去应对一场全球急难，并且与ZMapp的知识产权持有者签署了授权协议。“人们认为美加之间易于发展国际合作，他说，“但如今，中国也可以在其中发挥作用，有时能在应急药品的制作上“达成更好、更快的结果。

ZMapp is being tested in a clinical trial in the United States and Sierra Leone, where thegovernment reported nine new cases of Ebola on Thursday, one of the highest daily totals inmonths.